The purpose of this retrospective study was to analyze the development of malignancies after renal transplantation. 633 renal graft recipients with an organ function longer than 1 year were followed up over a mean period of 67.6 ± 48.7 months. Only 12 recipients received grafts from living-related donors. 38 recipients (6.0%) exhibited cancer of either the skin, the genitourinary system, the bronchial system, the female breast, or the colon. All tumors were de novo malignancies. The number of patients developing a tumor was significantly higher in the cyclosporine-treated group than in patients with conventional immunosuppression. 15 patients died within a mean survival time of 7.7 ± 12.1 months. The frequency of disorders makes it necessary for organ transplant recipients to have routine examinations both before and at regular intervals after transplantation. This includes examination of the patient’s skin, native kidneys and cervical smears for females.

Keywords:
Renal transplantation, Immunosuppression, Malignant tumors
This content is only available via PDF.
© 1996 S. Karger AG, Basel
1996
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.